ON101

PA-F4, comes from an extract of Plectranthus amboinicus, a perennial herb that grows in warm climates. The second, S1, is obtained from an extract of Centella asiatica, a herb from East Asia

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cao, Yemin: 1 article (01/2021)
2.	Cazzell, Shawn M: 1 article (01/2021)
3.	Chang, Shun-Cheng: 1 article (01/2021)
4.	Chen, Hsin-Han: 1 article (01/2021)
5.	Cheng, Nai-Chen: 1 article (01/2021)
6.	Huang, Hsuan-Li: 1 article (01/2021)
7.	Huang, Kuo-Feng: 1 article (01/2021)
8.	Huang, Yu-Yao: 1 article (01/2021)
9.	Li, Qiu: 1 article (01/2021)
10.	Li, Yanbing: 1 article (01/2021)

Related Diseases

1.	Ulcer 09/01/2022 - "We found that topical treatment with ON101, a plant-based potential therapeutic for diabetic foot ulcers, increased M2c-like (CD163+ and CD206+) cells and suppressed M1-like cells, altering the inflammatory gene profile in a diabetic mouse model compared with that in the controls. " 01/01/2023 - "To assess the cost-effectiveness of an ON101 cream added on to general wound care (GWC; ie, conventional treatments for DFUs, which comprised initial and regular foot examinations, ulcer management, comorbidity control, patient education, and multidisciplinary care) vs GWC alone for DFUs from the Taiwan health care sector perspective. " 01/01/2021 - "In this multicenter randomized clinical trial, ON101 exhibited better healing efficacy than absorbent dressing alone in the treatment of DFUs and showed consistent efficacy among all patients, including those with DFU-related risk factors (glycated hemoglobin level, ≥9%; ulcer area, >5 cm2; and DFU duration, ≥6 months). " 01/01/2021 - "In the FAS, 236 eligible patients (175 men [74.2%]; mean [SD] age, 57.0 [10.9] years; mean [SD] glycated hemoglobin level, 8.1% [1.6%]) with DFUs classified as Wagner grade 1 or 2 (mean [SD] ulcer area, 4.8 [4.4] cm2) were randomized to receive either the ON101 cream (n = 122) or the absorbent dressing (n = 114) for as long as 16 weeks. "
2.	Diabetic Foot 09/01/2022 - "We found that topical treatment with ON101, a plant-based potential therapeutic for diabetic foot ulcers, increased M2c-like (CD163+ and CD206+) cells and suppressed M1-like cells, altering the inflammatory gene profile in a diabetic mouse model compared with that in the controls. "
3.	Disease Progression 01/01/2023 - "In this economic evaluation study using a simulated patient cohort, the ON101 with GWC strategy represented good value compared with GWC alone for patients with DFUs from the Taiwan health care sector perspective and may be prioritized for those with high risks for disease progression of DFUs."
4.	Wounds and Injuries (Trauma) 09/27/2022 - "ON101, the newest clinically approved product in this setting, is designed specifically to down-regulate M1 macrophages and further modulate the wound microenvironment to favour M2 emergence and expansion. " 01/01/2023 - "To assess the cost-effectiveness of an ON101 cream added on to general wound care (GWC; ie, conventional treatments for DFUs, which comprised initial and regular foot examinations, ulcer management, comorbidity control, patient education, and multidisciplinary care) vs GWC alone for DFUs from the Taiwan health care sector perspective. "
5.	Inflammation (Inflammations) 09/01/2022 - "Thus, ON101 directly suppressed M1 macrophages and facilitated the GCSF- and CXCL3-mediated transition from M1 to M2 macrophages, lowering inflammation and leading to faster diabetic wound healing."

Related Drugs and Biologics

1.	Glycated Hemoglobin (Glycosylated Hemoglobin)

Related Therapies and Procedures

1.	Surgical Amputation (Amputations)